Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Achillion Pharmaceuticals has reported positive top-line results from its ongoing Phase 2a clinical trial evaluating ACH-1625 in patients with chronic hepatitis C (HCV) infection.
Subscribe to our email newsletter
In the first of a two segment Phase 2a trial, 64 patients were enrolled and randomised to receive three doses of ACH-1625 given once daily (200mg, 400mg or 800mg) or placebo with peginterferon alfa-2a and ribavirin, a current standard of care.
The patients were dosed for 4 weeks of therapy, which was then followed by standard of care for 44 weeks.
The study results showed that 75-81% of patients treated with ACH-1625 achieved rapid virologic response (RVR) with a promising safety and tolerability profile.
ACH-1625 is a HCV protease inhibitor designed and synthesized based on crystal structures of enzyme/inhibitor complex.
It is an open chain, non-covalent, reversible inhibitor of NS3 protease.
In preclinical studies, ACH-1625 demonstrated high potency, unique pharmacokinetic properties and an excellent safety profile at high drug exposures